Chi-Med Extends Oncology Commercial Reach To Realize China Potential

Sales Force Grows Nearly 10-Fold

 
• By Brian Yang

Chi-Med has revised its commercial rights agreement in China for Elunate (fruquintinib) with Lilly to seize China’s rapid growth trajectory, CEO Christian Hogg tells Scrip.

China flag with arrow graph going up showing strong economy and shares rise. Profit and success. Isolated vector illustration.
CHIMED EXPANDS COMMERCIAL ACTIVITIES IN CHINA TO DRIVE GROWTH FOR CANCER DRUG • Source: Shutterstock

More from China

More from Focus On Asia